Inhibrx Biosciences Inc. Common Stock (INBX)

About INBX

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candid…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

109

Website

inhibrx.com/

Fundamentals

1-day range

$80.42$89.28

Market cap

$1.26B

P/E (trailing)

—

P/E (forward)

-14.07

EPS (trailing)

$-8.39

Dividend yield

—

Beta

3.12

Avg. volume

355.1K

Forecasts

2 analyst ratings

Inhibrx Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• INBX

  Inhibrx Biosciences Inc. Common Stock

  $123.93

  ▼ 0.00%
  Market cap $1.26BP/E —
  $26.19$155.29
• IMTX

  Immatics N.V. Ordinary Shares

  $9.45

  ▲ 0.91%
  Market cap $1.26BP/E —
  $5.05$12.41
• NVAX

  Novavax Inc. Common Stock

  $9.27

  ▲ 2.43%
  Market cap $1.27BP/E —
  $6.2$11.97
• VOR

  Vor Biopharma Inc. Common Stock

  $22.66

  ▼ 3.70%
  Market cap $1.28BP/E —
  $6.5$49.95
• GLUE

  Monte Rosa Therapeutics Inc. Common Stock

  $13.37

  ▼ 6.63%
  Market cap $1.33BP/E —
  $4.6$25.77
• ALVO

  Alvotech Ordinary Shares

  $4.95

  ▲ 1.43%
  Market cap $1.19BP/E —
  $2.94$9.25
• MGTX

  MeiraGTx Holdings plc Ordinary Shares

  $13.8

  ▼ 2.40%
  Market cap $1.18BP/E 17.21
  $6.62$15.35

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245
  benzinga · 8/24/2026
• HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245
  Benzinga · 8/24/2026

• Kristiina Vuori, MD · June 3, 2026 · Grant

  15.0K
• Jon Faiz Kayyem · June 3, 2026 · Grant

  15.0K
• Douglas Forsyth · June 3, 2026 · Grant

  15.0K
• Kimberly Manhard · June 3, 2026 · Grant

  15.0K
• Matly David · April 24, 2026 · Grant

  50.0K

Institutional Ownership

March 31, 2026

Total shares held

12.91M

Total value held

$866.67M

Institutional holders

131